Premium
DT‐02‐04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS
Author(s) -
Palmqvist Sebastian,
Janelidze Shorena,
Stomrud Erik,
Zetterberg Henrik,
Karl Johann,
Mattsson Niklas,
Blennow Kaj,
Eichenlaub Udo,
Hansson Oskar
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.07.013
Subject(s) - medicine , dementia , apolipoprotein e , biomarker , cognitive decline , logistic regression , receiver operating characteristic , population , cognitive impairment , area under the curve , memory clinic , oncology , gastroenterology , disease , biology , biochemistry , environmental health
baseline. The median percentage change was -42% in the IVarm and -48% in the SC arm, with 21% and 13% of patients falling below the LLoQ after treatment. In contrast, no systematic change was observed in the placebo group, with a median change of -13% and equivalent portions with negative and positive change (54% of the placebo patients had lower AbO levels at week 69). The difference in proportions of patients with decreasing levels was significant for both treatment arms: p1⁄40.001 for SC, and p1⁄40.01 for IV crenezumab vs. placebo. Conclusions:Crenezumab lowers AbO levels in CSF in the large majority of tested patients. These results strongly suggest engagement of the principal target and recommend assaying CSF AbO in future trials of anti-Ab agents.